Ignite Creation Date:
2024-05-06 @ 9:14 AM
Last Modification Date:
2024-10-26 @ 12:11 PM
Study NCT ID:
NCT02935153
Status:
UNKNOWN
Last Update Posted:
2019-06-25
First Post:
2016-10-14
Brief Title:
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
Sponsor:
Southwest Hospital China
Organization:
Southwest Hospital China
Study Overview
Official Title:
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
Status:
UNKNOWN
Status Verified Date:
2019-06
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The overall purpose of this study is to explore the therapeutic effect of CD22-targeted chimeric antigen receptor TCAR-T cells in the treatment of Malignant B-cell Derived Leukemia and Lymphoma
Detailed Description:
CD22 is a type I transmembrane protein expressed on most mature B lymphocyte in the B cell malignanciesand plays a significant role in signal transduction pathwaysDespite of the fact that CD19-targeted CAR-T can re-induce remissions for many patients with relapsed and refractory B cell malignancies a part of those patients will relapse with CD19-negative malignancies To explore a rescue for those with CD19-negative B cell malignancies we design and conduct this trial to test the safety and effectiveness of CD22-targeted CAR-T
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None